← Leaderboards
Arthur P Bertolino
Cytoagents, Inc.
$3,313,557
Attributed
$3,313,557
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.3M · FY2024–25$2.5M$1.9M$1.3M$625K$0
'24
'25
Funding mix
By agency
NIH$3,313,557 · 2
By mechanism
R44$3,313,557 · 2
Top collaborators
No co-investigators on record.
Others in their field
Other Rising Stars on “Dose”
- Sabrina Paganoni · Massachusetts General Hospital$26,348,733
- Suma Babu · Massachusetts General Hospital$26,348,733
- Michael Difilippantonio · Leidos Biomedical Research, Inc.$22,364,766
- Supriya Menezes · The Emmes Company, Llc$18,394,958
- Xuping Xie · University Of Texas Med Br Galveston$13,737,799
- Dawn Fallacara · Battelle Centers/Pub Hlth Res & Evaluatn$13,673,728
Research focus
DoseEtiologyDinoprostoneAdverse EventDrug KineticsEpoprostenolArterial Occlusive DiseasesCd19 GeneAsianCellsChimeric Antigen Receptor T CellsChronicEndothelial CellsClinical AssessmentsClinical InvestigationCar T Cell TherapyClinical TrialsCohortCountryCovid-19CytokineCytokine Release SyndromeDangerousnessFormulation
Grant awards (3)
CTO1681 to prevent and mitigate cytokine release syndrome in multiple myeloma patients receiving CAR T-cell therapy$1,313,567
R44 · FY2025 · CA · contact PI
CTO1681 to prevent and mitigate cytokine release syndrome in CAR T-cell recipients$1,005,131
R44 · FY2025 · CA · contact PI
CTO1681 to prevent and mitigate cytokine release syndrome in CAR T-cell recipients$994,859
R44 · FY2024 · CA · contact PI